- Home
- UHG vs PBYI Comparison
UHG vs PBYI Comparison
Compare UHG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- PBYI
- Stock Information
- Founded
- UHG 2004
- PBYI 2010
- Country
- UHG United States
- PBYI United States
- Employees
- UHG N/A
- PBYI N/A
- Industry
- UHG Homebuilding
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- PBYI Health Care
- Exchange
- UHG Nasdaq
- PBYI Nasdaq
- Market Cap
- UHG 158.8M
- PBYI 164.3M
- IPO Year
- UHG N/A
- PBYI N/A
- Fundamental
- Price
- UHG $3.14
- PBYI $3.45
- Analyst Decision
- UHG
- PBYI Strong Buy
- Analyst Count
- UHG 0
- PBYI 1
- Target Price
- UHG N/A
- PBYI $7.00
- AVG Volume (30 Days)
- UHG 231.7K
- PBYI 311.7K
- Earning Date
- UHG 08-07-2025
- PBYI 07-31-2025
- Dividend Yield
- UHG N/A
- PBYI N/A
- EPS Growth
- UHG N/A
- PBYI 143.51
- EPS
- UHG 0.76
- PBYI 0.77
- Revenue
- UHG $449,877,017.00
- PBYI $232,709,000.00
- Revenue This Year
- UHG N/A
- PBYI N/A
- Revenue Next Year
- UHG N/A
- PBYI N/A
- P/E Ratio
- UHG $4.06
- PBYI $4.39
- Revenue Growth
- UHG 5.24
- PBYI 2.68
- 52 Week Low
- UHG $1.60
- PBYI $2.23
- 52 Week High
- UHG $6.93
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- UHG 49.50
- PBYI 50.12
- Support Level
- UHG $2.71
- PBYI $3.26
- Resistance Level
- UHG $2.95
- PBYI $3.68
- Average True Range (ATR)
- UHG 0.33
- PBYI 0.12
- MACD
- UHG -0.07
- PBYI 0.00
- Stochastic Oscillator
- UHG 28.24
- PBYI 52.90
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.